Methodological limitations of the ESRD Core Indicators Project: an ESRD network's experience with implementing an ESRD quality survey. Medical Review Board of the ESRD Network of New England.
ESRD Network Number 1, composed of Maine, New Hampshire, Vermont, Massachusetts, Connecticut, and Rhode Island, developed a Network Core Indicator Pilot Project using the dialysis units represented on the Medical Review Board. Network 1's Core Indicator Pilot Project aimed to (1) estimate the proportion of end-stage renal disease (ESRD) patients in Network 1 receiving hemodialysis treatments associated with a urea reduction ratio less than 60% to 65%, (2) elucidate the patient characteristics associated with a hemodialysis dose less than 65%, (3) define the processes in the delivery of hemodialysis that limit the provision of an adequate dialysis dose, and (4) initiate the routine collection of measures of dialysis dose, the analysis of those data, and feedback to the participating dialysis units. In the course of the Core Indicator Pilot Project, we observed little uniformity in the sampling method for the postdialysis blood urea nitrogen sample. Thirty-three percent of the hemodialysis units reported that this critical blood sample was drawn immediately before the dialysis treatment was terminated; 25% were obtained immediately at the end of the dialysis treatment and 42% drew the sample > or = 5 minutes after all blood was reinfused to the patient. Especially in the presence of unappreciated blood recirculation in the angioaccess or postdialysis urea rebound, the lack of standardization in obtaining this critical blood sample to support the urea reduction ratio calculation greatly compromises any comparisons of performance across dialysis facilities and may jeopardize patient care. Future ESRD quality improvement efforts must focus not only on the results of the outcome measure but also on the process by which the measure is achieved. These fundamental principles of quality assessment should be considered by policy specialists, payers, providers, and developers of clinical practice guidelines.